Contingent assessment of the COVID-19 vaccine
| dc.creator | García, Leidy Y. | |
| dc.creator | Cerda, Arcadio A. | |
| dc.date.accessioned | 2020-06-26T11:56:33Z | |
| dc.date.available | 2020-06-26T11:56:33Z | |
| dc.date.issued | 2020 | |
| dc.description.abstract | The COVID-19 pandemic has not only had a negative impact on people’s health and life behavior, but also on economies around the world. At the same time, laboratories and institutions are working hard to obtain a COVID-19 vaccine, which we hope will be available soon. However, there has been no assessment of whether an individual and society value a vaccine monetarily, and what factors determine this value. Therefore, the objective of this research was to estimate the individual’s willingness to pay (WTP) for a hypothetical COVID-19 vaccine and, at the same time, find the main factors that determine this valuation. For this, we used the contingent valuation approach, in its single and double-bounded dichotomous choice format, which was based on a hypothetical market for a vaccine. The sample used was obtained through an online survey of n = 566 individuals from Chile. The main results showed that the WTP depends on the preexistence of chronic disease (), knowledge of COVID-19 (), being sick with COVID-19 (), perception of government performance (), employment status (), income (), health care (), adaptation to quarantine with children at home ( and whether the person has recovered from COVID-19 (. According to our discrete choice model in double-bounded dichotomous format, it was concluded that the individuals’ WTP is US$184.72 (CI: 165.52-203.92; p < 0.01). This implies a social valuation of approximately US$2,232 million, corresponding to 1.09% of the GNP per capita. | pt_BR |
| dc.identifier.citation | GARCÍA, L. Y.; CERDA, A. A. Contingent assessment of the COVID-19 vaccine. Vaccine, [S.l.], 2020. No prelo. | pt_BR |
| dc.identifier.uri | https://repositorio.ufla.br/handle/1/41577 | |
| dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0264410X20308549 | pt_BR |
| dc.language | en_US | pt_BR |
| dc.publisher | Elsevier | pt_BR |
| dc.rights | openAccess | pt_BR |
| dc.source | Vaccine | pt_BR |
| dc.subject | COVID-19 | pt_BR |
| dc.subject | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | pt_BR |
| dc.subject | Vaccine | pt_BR |
| dc.subject | Health economics | pt_BR |
| dc.subject | Contingent valuation | pt_BR |
| dc.title | Contingent assessment of the COVID-19 vaccine | pt_BR |
| dc.type | Artigo | pt_BR |
Arquivos
Licença do pacote
1 - 1 de 1
Carregando...
- Nome:
- license.txt
- Tamanho:
- 953 B
- Formato:
- Item-specific license agreed upon to submission
- Descrição:
